We built unique Drug candidate for treatment of pandemic Pancreatic Cancer

We starting Pancreatic Pharmaceuticals – spin off company of Micar Innovation and go ahead to Preclinical & Clinical phases ...

Pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S.

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market was valued at US$3,397.5 mn in 2016 and is projected to reach US$6,414.4 mln by 2025, expanding at a CAGR of 7.2% from 2017 to 2025 Source: https://www.transparencymarketresearch.com/exocrine-pancreatic-insufficiency.html